EBGLYSS (lebrikizumab-lbkz)

**Product type:** Human Prescription Drug

**Active ingredient:** LEBRIKIZUMAB

**Strength:** 250 mg/2mL

**Dosage form:** Injection, Solution

**Route:** Subcutaneous

**Labeler:** Eli Lilly and Company

**Marketing category:** BLA (BLA761306)

**Pharmacologic class:** Interleukin-13 Antagonist [EPC], Interleukin-13 Antagonists [MoA]